Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RPRX - Royalty Pharma plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$56.67
DETAILS
HIGH:
$63.00
LOW:
$50.00
MEDIAN:
$57.00
CONSENSUS:
$56.67
UPSIDE:
0.72%
Stock News
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma's positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers.
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma to present at upcoming investor conferences
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.3 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.06 per share a year ago.
Royalty Pharma reports first quarter 2026 results
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma has delivered a strong start to 2026 across multiple dimensions.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives.
Price Targets
Royalty Pharma price target raised to $57 from $51 at UBS
$57.00
(was $49.30)
Ashwani Verma
·
UBS
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
$63.00
(was $47.98)
Terence Flynn
·
Morgan Stanley
Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen
$50.00
(was $46.21)
Seaport Global
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
$61.00
(was $44.71)
Terence Flynn
·
Morgan Stanley
Royalty Pharma upgraded to Buy from Neutral at UBS
$49.00
(was $40.86)
Ashwani Verma
·
UBS
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business'
$45.00
(was $38.22)
Leerink Partners
Royalty Pharma initiated with a Buy at Goldman Sachs
$42.00
(was $35.25)
Goldman Sachs
Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
$54.00
(was $36.14)
Terence Flynn
·
Morgan Stanley
Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
$51.00
(was $29.16)
Chris Shibutani
·
Goldman Sachs
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
$51.00
(was $25.73)
Terence Flynn
·
Morgan Stanley
Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs
$50.00
(was $27.09)
Chris Shibutani
·
Goldman Sachs
Royalty Pharma downgraded to Neutral from Buy at UBS
$28.00
(was $27.35)
Ashwani Verma
·
UBS
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $51
$51.00
(was $42.87)
Morgan Stanley
Royalty Pharma initiated with a Buy at UBS
$47.00
(was $38.46)
Ashwani Verma
·
UBS